SMS Lifesciences India Ltd

SMS Lifesciences India Ltd

$SMSLIFEPharmaceuticalsNSEBSE

SMS Lifesciences India Ltd (SMSLIFE) last traded at ₹1,550, a market capitalisation of ₹469 crore, on a P/E of 29.6. Over the past 52 weeks the stock has ranged between ₹1,076 and ₹1,778. SMS Lifesciences India Ltd last reported results for the quarter ended Jun 2026, with sales of ₹72.94 crore and net profit of ₹1.84 crore. SMS Lifesciences India Ltd’s annual general meeting is scheduled for 30 Sept 2026. Figures are as of 25 Aug 2026 and are not real time.

SMS Lifesciences India Ltd share price and key metrics

Current price
₹1,550
Market cap
₹469 cr
Stock P/E
29.6
Book value
₹706
ROE
8.44%
ROCE
9.91%
Dividend yield
0.09%
52w high / low
1778/1076

Metrics as of 25 Aug 2026. Not real time.

SMS Lifesciences India Ltd quarterly results

In the quarter ended Jun 2026, sales were ₹72.94 cr, down 11.6% from ₹82.5 cr a year earlier. Net profit was ₹1.84 cr, down 58.1% year on year.

SMS Lifesciences India Ltd consolidated quarterly results, figures in ₹ crore
₹ croreSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales78.4684.689.1182.581.3794.7875.1472.94
Expenses69.8971.8581.6970.7967.7980.7370.9863.82
Operating profit8.5712.757.4211.7113.5814.054.169.12
OPM %10.92%15.07%8.33%14.19%16.69%14.82%5.54%12.50%
Other income2.040.062.3410.420.182.010.46
Interest2.142.142.031.871.621.541.421.9
Depreciation3.763.763.83.823.893.913.854.24
Profit before tax4.716.913.937.028.498.780.93.44
Tax %29.72%29.81%11.45%37.61%24.38%24.26%62.22%46.51%
Net profit3.34.863.484.396.426.650.351.84
EPS (₹)15.4518.099.8213.7620.1821.901.468.77

Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.

SMS Lifesciences India Ltd annual results

SMS Lifesciences India Ltd annual profit and loss, figures in ₹ crore
₹ croreMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales266350316306345334324
Operating profit30352931454541
OPM %11%10%9%10%13%13%13%
Net profit1425116191815
EPS (₹)44.8583.7537.9130.0766.5257.2652.31

TTM is the trailing twelve months to the most recent quarter.

SMS Lifesciences India Ltd growth and returns

Compounded Sales Growth
10 Years
%
5 Years
5%
3 Years
2%
TTM
-3%
Compounded Profit Growth
10 Years
%
5 Years
5%
3 Years
20%
TTM
-8%
Stock Price CAGR
10 Years
%
5 Years
16%
3 Years
44%
1 Year
36%
Return on Equity
10 Years
%
5 Years
8%
3 Years
8%
Last Year
8%

SMS Lifesciences India Ltd shareholding pattern

Promoters held 72.10% at Jun 2026, up from 71.40% at Jun 2025. FIIs 0.00% and DIIs 0.31%.

SMS Lifesciences India Ltd shareholding pattern by quarter, in percent
% heldSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters71.40%71.40%71.40%71.40%71.40%71.79%72.10%72.10%
FIIs0.02%0.00%0.00%0.03%0.00%0.00%0.00%0.00%
DIIs0.00%0.00%0.00%0.00%0.03%0.29%0.30%0.31%
Public28.57%28.59%28.60%28.56%28.57%27.91%27.59%27.58%
No. of shareholders7,8497,6267,4797,4127,5217,1256,9376,859

As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.

When is SMS Lifesciences India Ltd’s AGM?

SMS Lifesciences India Ltd’s annual general meeting is scheduled for 30 Sept 2026.

  • AGMHolding the 20th Annual General Meeting

See the full results calendar for every Indian company reporting in the next 30 days.

SMS Lifesciences India Ltd corporate filings

  • Enclosed email communication sent to Shareholders.Company Updatelow impact
    Filing PDF

    Cruxal's analysis: Haleos Labs Ltd has issued a standard communication to its shareholders regarding Tax…

    Read the full analysis
  • Enclosed -- newspaper advertisement for Q1F27 results.Company Updatelow impact
    Filing PDF

    Cruxal's analysis: Haleos Labs Limited (formerly SMS Lifesciences India Limited) has published its financial…

    Read the full analysis
  • Mahi Drugs Private Limited appointed Cost Auditors for the year 2026-27 and Mr. Vincent P Asrao as Nominee Director.Company Updatelow impact
    Filing PDF

    Cruxal's analysis: Haleos Labs Ltd has appointed a Cost Auditor for the financial year 2026-27 and…

    Read the full analysis
  • Dr. Mannam Malakondaiah and Dr. Srinivas Samavedam were reappointed for a second term of 5 years w.e.f. November 13, 2026, subject to approval of shareholders.Company Updatelow impact
    Filing PDF

    Cruxal's analysis: Haleos Labs Ltd has proposed the reappointment of Dr. Mannam Malakondaiah and Dr…

    Read the full analysis
  • Enclosed - Outcome of 98th Board meeting.Board Meetingmedium impact
    Filing PDF

    Cruxal's analysis: Haleos Labs Limited (formerly SMS Lifesciences India Limited) reported standalone revenue…

    Read the full analysis

This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.

Track SMS Lifesciences India Ltd

Cruxal reads every SMS Lifesciences India Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.

Cruxal publishes market data and coverage for information only. Nothing here is investment advice.

SMS Lifesciences India Ltd (SMSLIFE) Results, Financials & Share Price | Cruxal